A new review suggests cannabis may help mental health disorders
Legal access to marijuana, medicinal or otherwise,
is growing. In 2016, four states approved recreational use of the drug
and four states passed laws related to medical-cannabis access, bringing
the total number of states that allow some form of legal marijuana use to 28.
Scientists know that marijuana contains
more than 100 compounds, called cannabinoids, that have biological
effects on the body. Mdically, cannabis can be prescribed for physical
ailments like arthritis and cancer symptoms as well as mental health
issues like PTSD, depression and anxiety.
Still, the role marijuana can
play in medicine remains murky. The dearth of
research is in large part due to the fact that most studies have focused
on illicit use of marijuana rather than its therapeutic potential, and
because it’s classified as a schedule 1 drug, making it nearly
impossible to study.
Looking for answers about marijuana’s
potential mental health benefits, a team of researchers in Canada and
the U.S. recently conducted a review of the science. In their report,
published in the journal Clinical Psychology Review, researchers
found evidence that cannabis can likely benefit people dealing with
depression, social anxiety and PTSD, though it may not be ideal for
people with bipolar disorder, for instance, for which there appears to
be more negative side effects than positive ones.
“This
is a substance that has potential use for mental health,” says Zach
Walsh, an associate professor of psychology at the University of British
Columbia. “We should be looking at it in the same way [as other drugs]
and be holding it up to the same standard.”
Though more research is needed, studies also suggested that cannabis may have a place in dealing with addiction. “We
are really excited about the potential substitution effect,” says study
author Zach Walsh, an associate professor of psychology at the
University of British Columbia. “If people use cannabis as a replacement
for opioid medications, or to get off of opioids or cut back, we could
see some pretty dramatic public health benefits. The level of opioid
overdoses is so high right now.”
There’s evidence to support that potential. Another unrelated study suggested that pot may even have a place in curbing the opioid epidemic.
And yet marijuana can be notoriously hard to study in the U.S. because
it’s classified as a Schedule 1 drug, which means it has a high
potential for abuse. Many scientists and medical professionals think the
classification hampers research, and that marijuana’s medical potential
merits further exploration. More studies, research advocates argue,
would also help eliminate stigma associated with the drug, paving the
way for more and better studies.
“I think people will derive more benefit if they can speak
more openly with providers about whether they are using cannabis and
why,” says Walsh.
Walsh is a lead investigator on a clinical trial of cannabis that is
being funded by a medical cannabis producer called Tilray. Another
researcher on the study has been a consultant for other medical cannabis
producers. When asked if this represents a conflict of interest, Walsh
points out that funding for marijuana-related research is hard to come
by. “I think we are entering a different world,” he
says, “but for now a lot of the research, at least in Canada, is funded
by the producers.”
No comments:
Post a Comment